18 F-FGln PET/CT Imaging Shows High Uptake in Meningiomas Providing Insights for Diagnosis and Treatment.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40938197.
- Also identified by DOI 10.1097/RLU.0000000000006080.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 64-year-old woman with persistent headaches and vision disturbances underwent 18 F-(2S,4R)-4-fluoroglutamine ( 18 F-FGln) PET/CT due to MRI contraindications. Imaging revealed a sellar mass with high radiotracer uptake (SUVmax 7.17), later confirmed as a WHO grade I meningioma. This case highlights the potential of 18 F-FGln PET/CT in detecting meningiomas, leveraging their glutamine metabolism. Given the tumor's metabolic profile, glutaminase inhibitors may offer novel therapeutic avenues. Further research is warranted to explore the mechanistic basis of 18 F-FGln uptake in meningiomas and its implications for diagnosis and treatment.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Glutamine
- Meningioma
- Meningeal Neoplasms